Clinical Trials Browser

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT01791387 2015-02-03

DILIGENCE-1

Phase 2 Unknown

30 enrolled

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT01556815 2012-04-25

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Phase 2 Unknown

40 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT01533324 2012-02-15

S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

32 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Liver Diseases

NCT01216371 2012-02-13

SMAT

Phase 2 Unknown

60 enrolled

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00905983 2009-05-21

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 2 Unknown

48 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00894569 2009-05-14

PACET-CUP

Phase 2 Unknown

150 enrolled

Tumor-Agnostic

Carcinoma, Neoplasms, Unknown Primary

Clinical Trials

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

DUNCAN

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

TIDE-A

ANLOLA

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

DILIGENCE-1

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)

SMAT

Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients

PACET-CUP